Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III non-small cell lung cancer

Hyun Chang, S. E.Hyun Kim, ByoungChul Cho, Sang Hyun Yoon, Hye Ryun Kim, Chang Geol Lee, Joo Hang Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background/Aim: We evaluated the anti-tumor activity and safety of cisplatin with irinotecan (IP) induction chemotherapy followed by chemoradiotherapy with etoposide/cisplatin (EP). Patients and Methods: Induction chemotherapy consisted of irinotecan i.v. and cisplatin i.v. and was administered on day 1 and day 8 of each cycle. Patients underwent two cycles of chemotherapy with a 3-week interval. In the absence of progressive disease, 66 Gy radiation was administered concurrently with etoposide on days 1 to 5 and 29 to 33, as well as with cisplatin on day 1, 8, 29, and 36. Results: Twenty patients were enrolled between July 2007 and December 2009. This study was closed prematurely due to lack of efficacy in induction chemotherapy. The overall response rate was 45% [95% confidence interval (CI), 25 to 65%], which did not meet the upper limit for first stage rejection of the treatment. The rates of 3-year progression-free survival and overall survival were 17.1% (95% CI, 0 to 36.8%) and 25% (95% CI, 0.2 to 49.8%), respectively. The primary toxicities included neutropenia, diarrhea and fatigue. Conclusion: This study failed to demonstrate a benefit for induction chemotherapy which was characterized by suboptimal antitumor activity and was poorly tolerated, with excess treatment-related toxicity.

Original languageEnglish
Pages (from-to)3515-3521
Number of pages7
JournalAnticancer Research
Volume32
Issue number8
Publication statusPublished - 2012 Aug 1

Fingerprint

irinotecan
Induction Chemotherapy
Chemoradiotherapy
Non-Small Cell Lung Carcinoma
Cisplatin
Etoposide
Confidence Intervals
Radiation Dosage
Neutropenia
Disease-Free Survival
Fatigue
Diarrhea
Safety
Drug Therapy
Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Chang, Hyun ; Kim, S. E.Hyun ; Cho, ByoungChul ; Yoon, Sang Hyun ; Kim, Hye Ryun ; Lee, Chang Geol ; Kim, Joo Hang. / Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III non-small cell lung cancer. In: Anticancer Research. 2012 ; Vol. 32, No. 8. pp. 3515-3521.
@article{18d5344543624ee2a4be09b42a238bd3,
title = "Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III non-small cell lung cancer",
abstract = "Background/Aim: We evaluated the anti-tumor activity and safety of cisplatin with irinotecan (IP) induction chemotherapy followed by chemoradiotherapy with etoposide/cisplatin (EP). Patients and Methods: Induction chemotherapy consisted of irinotecan i.v. and cisplatin i.v. and was administered on day 1 and day 8 of each cycle. Patients underwent two cycles of chemotherapy with a 3-week interval. In the absence of progressive disease, 66 Gy radiation was administered concurrently with etoposide on days 1 to 5 and 29 to 33, as well as with cisplatin on day 1, 8, 29, and 36. Results: Twenty patients were enrolled between July 2007 and December 2009. This study was closed prematurely due to lack of efficacy in induction chemotherapy. The overall response rate was 45{\%} [95{\%} confidence interval (CI), 25 to 65{\%}], which did not meet the upper limit for first stage rejection of the treatment. The rates of 3-year progression-free survival and overall survival were 17.1{\%} (95{\%} CI, 0 to 36.8{\%}) and 25{\%} (95{\%} CI, 0.2 to 49.8{\%}), respectively. The primary toxicities included neutropenia, diarrhea and fatigue. Conclusion: This study failed to demonstrate a benefit for induction chemotherapy which was characterized by suboptimal antitumor activity and was poorly tolerated, with excess treatment-related toxicity.",
author = "Hyun Chang and Kim, {S. E.Hyun} and ByoungChul Cho and Yoon, {Sang Hyun} and Kim, {Hye Ryun} and Lee, {Chang Geol} and Kim, {Joo Hang}",
year = "2012",
month = "8",
day = "1",
language = "English",
volume = "32",
pages = "3515--3521",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "8",

}

Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III non-small cell lung cancer. / Chang, Hyun; Kim, S. E.Hyun; Cho, ByoungChul; Yoon, Sang Hyun; Kim, Hye Ryun; Lee, Chang Geol; Kim, Joo Hang.

In: Anticancer Research, Vol. 32, No. 8, 01.08.2012, p. 3515-3521.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III non-small cell lung cancer

AU - Chang, Hyun

AU - Kim, S. E.Hyun

AU - Cho, ByoungChul

AU - Yoon, Sang Hyun

AU - Kim, Hye Ryun

AU - Lee, Chang Geol

AU - Kim, Joo Hang

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Background/Aim: We evaluated the anti-tumor activity and safety of cisplatin with irinotecan (IP) induction chemotherapy followed by chemoradiotherapy with etoposide/cisplatin (EP). Patients and Methods: Induction chemotherapy consisted of irinotecan i.v. and cisplatin i.v. and was administered on day 1 and day 8 of each cycle. Patients underwent two cycles of chemotherapy with a 3-week interval. In the absence of progressive disease, 66 Gy radiation was administered concurrently with etoposide on days 1 to 5 and 29 to 33, as well as with cisplatin on day 1, 8, 29, and 36. Results: Twenty patients were enrolled between July 2007 and December 2009. This study was closed prematurely due to lack of efficacy in induction chemotherapy. The overall response rate was 45% [95% confidence interval (CI), 25 to 65%], which did not meet the upper limit for first stage rejection of the treatment. The rates of 3-year progression-free survival and overall survival were 17.1% (95% CI, 0 to 36.8%) and 25% (95% CI, 0.2 to 49.8%), respectively. The primary toxicities included neutropenia, diarrhea and fatigue. Conclusion: This study failed to demonstrate a benefit for induction chemotherapy which was characterized by suboptimal antitumor activity and was poorly tolerated, with excess treatment-related toxicity.

AB - Background/Aim: We evaluated the anti-tumor activity and safety of cisplatin with irinotecan (IP) induction chemotherapy followed by chemoradiotherapy with etoposide/cisplatin (EP). Patients and Methods: Induction chemotherapy consisted of irinotecan i.v. and cisplatin i.v. and was administered on day 1 and day 8 of each cycle. Patients underwent two cycles of chemotherapy with a 3-week interval. In the absence of progressive disease, 66 Gy radiation was administered concurrently with etoposide on days 1 to 5 and 29 to 33, as well as with cisplatin on day 1, 8, 29, and 36. Results: Twenty patients were enrolled between July 2007 and December 2009. This study was closed prematurely due to lack of efficacy in induction chemotherapy. The overall response rate was 45% [95% confidence interval (CI), 25 to 65%], which did not meet the upper limit for first stage rejection of the treatment. The rates of 3-year progression-free survival and overall survival were 17.1% (95% CI, 0 to 36.8%) and 25% (95% CI, 0.2 to 49.8%), respectively. The primary toxicities included neutropenia, diarrhea and fatigue. Conclusion: This study failed to demonstrate a benefit for induction chemotherapy which was characterized by suboptimal antitumor activity and was poorly tolerated, with excess treatment-related toxicity.

UR - http://www.scopus.com/inward/record.url?scp=84865683181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865683181&partnerID=8YFLogxK

M3 - Article

C2 - 22843939

AN - SCOPUS:84865683181

VL - 32

SP - 3515

EP - 3521

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 8

ER -